Prostate Cancer

The novel oral TKI masitinib in combination with docetaxel and prednisone resulted in improved progression-free survival compared with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, meeting the predefined primary end point of the phase 2b/3 AB12003 trial.

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

A higher incidence of somatically acquired genetic alterations, including damaging mutations in ZMYM3 leading to genomic instability, as well as deletions in MAP3K7, BNIP3L, RB1, and NEIL3, and gain of MYC, may lead to more aggressive prostate cancer in Black/African American men.

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.

Natasha Garg, DO, discusses the impact of antiandrogens in the treatment of patients with nonmetastatic CRPC, shared advice for choosing among the available options, and projected what the future paradigm might look like.

Jason Zhu, MD, discusses the need to tailor therapy with androgen-deprivation therapy, radiation, and antiandrogen agents for men with pathologic and clinical node-positive prostate cancer.

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

Regulatory submissions for the combination of apalutamide plus abiraterone acetate and prednisone in the treatment of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer will not be pursued.

Jason Zhu, MD, discusses the role of androgen deprivation therapy in patients with pelvic node–positive prostate cancer.

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Maintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.

Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.

Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses future research directions with darolutamide for the treatment of patients with prostate cancer.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

The first-in-class N-terminal domain androgen receptor inhibitor EPI-7386 is being examined in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer as part of a phase 1/2 trial.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend an additional indication of enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival and radiographic progression-free survival over best standard care alone in patients with prostate specific membrane antigen–positive metastatic castration-resistant prostate cancer, meeting both primary end points of the phase 3 VISION trial.

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.

PARP inhibitors and novel combinations targeting the androgen receptor will help define the future treatment paradigm for patients with metastatic castration-resistant prostate cancer.

Bipolar androgen therapy demonstrated clinically meaningful activity and a good safety profile compared with enzalutamide in asymptomatic men with metastatic castration-resistant prostate cancer who progressed on abiraterone acetate.